| __timestamp | Soleno Therapeutics, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2917513 | 7461000 |
| Thursday, January 1, 2015 | 7878291 | 11960000 |
| Friday, January 1, 2016 | 8366794 | 13108000 |
| Sunday, January 1, 2017 | 6610381 | 17501000 |
| Monday, January 1, 2018 | 6556000 | 22472000 |
| Tuesday, January 1, 2019 | 6930000 | 24286000 |
| Wednesday, January 1, 2020 | 8758000 | 29689000 |
| Friday, January 1, 2021 | 10806000 | 38837000 |
| Saturday, January 1, 2022 | 9844000 | 47489000 |
| Sunday, January 1, 2023 | 13481000 | 53379000 |
Unleashing insights
In the competitive world of biotechnology, managing operational costs is crucial for success. Over the past decade, Soleno Therapeutics, Inc. and Xencor, Inc. have navigated their financial landscapes with varying strategies. From 2014 to 2023, Xencor's Selling, General, and Administrative (SG&A) expenses surged by over 600%, peaking at approximately $53 million in 2023. This reflects a strategic expansion, possibly linked to increased R&D and market penetration efforts. In contrast, Soleno's SG&A expenses grew by about 360%, reaching around $13 million in 2023. This more conservative growth suggests a focus on streamlined operations and targeted investments. The data highlights the diverse approaches these companies take in balancing growth and cost management, offering valuable insights into their strategic priorities in the ever-evolving biotech sector.
Breaking Down SG&A Expenses: Novo Nordisk A/S vs Soleno Therapeutics, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Soleno Therapeutics, Inc.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Catalent, Inc. and Soleno Therapeutics, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
Apellis Pharmaceuticals, Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Amicus Therapeutics, Inc. and Soleno Therapeutics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Catalyst Pharmaceuticals, Inc. vs Xencor, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Xencor, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Soleno Therapeutics, Inc. and Xencor, Inc.